M42 completed the investment in Juvenescence.

M42, an Abu Dhabi-based, global tech-enabled healthcare company, completed the investment in Juvenescence, a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines. Financial terms were not disclosed. "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi’s push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it’s about impact – on lives, on science and on the future of health,” Hasan Jasem Al Nowais, M42 Managing Director and Group CEO.